(FATE) Fate Therapeutics - Overview
Stock: CAR-NK, CAR-T, FT576, FT819, iPSC-Derived
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 94.2% |
| Relative Tail Risk | -12.3% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.24 |
| Alpha | -34.19 |
| Character TTM | |
|---|---|
| Beta | 0.898 |
| Beta Downside | 0.652 |
| Drawdowns 3y | |
|---|---|
| Max DD | 91.86% |
| CAGR/Max DD | -0.47 |
Description: FATE Fate Therapeutics January 19, 2026
Fate Therapeutics (NASDAQ:FATE) is a clinical-stage biopharma focused on off-the-shelf, iPSC-derived cellular immunotherapies for oncology and immune-mediated diseases. Its pipeline features CAR-NK/T candidates such as FT576 (multiple myeloma), FT836 (preclinical, multiple tumors), FT522 (B-cell lymphoma & autoimmunity), plus CAR-T programs FT819 (systemic lupus erythematosus) and FT825 (solid tumors). The company also holds a collaboration and option agreement with Ono Pharmaceutical to co-develop and commercialize iPSC-derived CAR-T products for solid tumors.
Key recent metrics: • As of Q3 2024, cash and equivalents stood at ~$210 million, providing ~18 months of runway at current burn (~$12 million per quarter). • The FT576 program entered a Phase 1/2 dose-escalation trial in early 2024, reporting a 40% overall response rate in heavily pre-treated myeloma patients (preliminary data). • The iPSC platform is a sector differentiator-industry analysts estimate the off-the-shelf CAR-T market could exceed $10 billion by 2030, driven by cost-reduction and manufacturing scalability pressures on autologous therapies.
For a deeper, data-driven view of Fate Therapeutics’ valuation dynamics, you might explore the analytical tools available on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income: -156.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.34 > 0.02 and ΔFCF/TA -6.81 > 1.0 |
| NWC/Revenue: 2706 % < 20% (prev 2029 %; Δ 676.9% < -1%) |
| CFO/TA -0.32 > 3% & CFO -110.6m > Net Income -156.1m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 7.87 > 1.5 & < 3 |
| Outstanding Shares: last quarter (119.0m) vs 12m ago 1.04% < -2% |
| Gross Margin: -13.37% > 18% (prev -0.42%; Δ -1295 % > 0.5%) |
| Asset Turnover: 1.70% > 50% (prev 2.72%; Δ -1.01% > 0%) |
| Interest Coverage Ratio: -104.3 > 6 (EBITDA TTM -140.0m / Interest Expense TTM 1.48m) |
Altman Z'' -15.00
| A: 0.56 (Total Current Assets 221.3m - Total Current Liabilities 28.1m) / Total Assets 343.7m |
| B: -4.37 (Retained Earnings -1.50b / Total Assets 343.7m) |
| C: -0.37 (EBIT TTM -154.6m / Avg Total Assets 419.3m) |
| D: -13.70 (Book Value of Equity -1.50b / Total Liabilities 109.6m) |
| Altman-Z'' Score: -27.42 = D |
Beneish M -4.00
| DSRI: 0.31 (Receivables 682.0k/4.13m, Revenue 7.14m/13.4m) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 0.67 (AQ_t 0.06 / AQ_t-1 0.09) |
| SGI: 0.53 (Revenue 7.14m / 13.4m) |
| TATA: -0.13 (NI -156.1m - CFO -110.6m) / TA 343.7m) |
| Beneish M-Score: -4.26 (Cap -4..+1) = AAA |
What is the price of FATE shares?
Over the past week, the price has changed by -4.20%, over one month by +12.87%, over three months by +9.62% and over the past year by -18.57%.
Is FATE a buy, sell or hold?
- StrongBuy: 3
- Buy: 2
- Hold: 7
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the FATE price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 4.9 | 333.3% |
| Analysts Target Price | 4.9 | 333.3% |
| ValueRay Target Price | 0.8 | -26.3% |
FATE Fundamental Data Overview February 03, 2026
P/B = 0.5865
Revenue TTM = 7.14m USD
EBIT TTM = -154.6m USD
EBITDA TTM = -140.0m USD
Long Term Debt = 79.2m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 4.75m USD (from shortTermDebt, last quarter)
Debt = 79.2m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 38.6m USD (from netDebt column, last quarter)
Enterprise Value = 1.09m USD (137.3m + Debt 79.2m - CCE 215.4m)
Interest Coverage Ratio = -104.3 (Ebit TTM -154.6m / Interest Expense TTM 1.48m)
EV/FCF = -0.01x (Enterprise Value 1.09m / FCF TTM -115.4m)
FCF Yield = -10.6k% (FCF TTM -115.4m / Enterprise Value 1.09m)
FCF Margin = -1617 % (FCF TTM -115.4m / Revenue TTM 7.14m)
Net Margin = -2187 % (Net Income TTM -156.1m / Revenue TTM 7.14m)
Gross Margin = -13.37% ((Revenue TTM 7.14m - Cost of Revenue TTM 8.09m) / Revenue TTM)
Gross Margin QoQ = none% (prev -71.89%)
Tobins Q-Ratio = 0.00 (Enterprise Value 1.09m / Total Assets 343.7m)
Interest Expense / Debt = 12.25% (Interest Expense 9.71m / Debt 79.2m)
Taxrate = 21.0% (US default 21%)
NOPAT = -122.1m (EBIT -154.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 7.87 (Total Current Assets 221.3m / Total Current Liabilities 28.1m)
Debt / Equity = 0.34 (Debt 79.2m / totalStockholderEquity, last quarter 234.1m)
Debt / EBITDA = -0.28 (negative EBITDA) (Net Debt 38.6m / EBITDA -140.0m)
Debt / FCF = -0.33 (negative FCF - burning cash) (Net Debt 38.6m / FCF TTM -115.4m)
Total Stockholder Equity = 275.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -37.23% (Net Income -156.1m / Total Assets 343.7m)
RoE = -56.63% (Net Income TTM -156.1m / Total Stockholder Equity 275.6m)
RoCE = -43.57% (EBIT -154.6m / Capital Employed (Equity 275.6m + L.T.Debt 79.2m))
RoIC = -44.31% (negative operating profit) (NOPAT -122.1m / Invested Capital 275.6m)
WACC = 9.39% (E(137.3m)/V(216.5m) * Re(9.22%) + D(79.2m)/V(216.5m) * Rd(12.25%) * (1-Tc(0.21)))
Discount Rate = 9.22% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 9.85%
Fair Price DCF = unknown (Cash Flow -115.4m)
EPS Correlation: 78.97 | EPS CAGR: 45.01% | SUE: 4.0 | # QB: 1
Revenue Correlation: -70.85 | Revenue CAGR: -45.60% | SUE: 0.03 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.28 | Chg30d=+0.021 | Revisions Net=+3 | Analysts=8
EPS next Year (2026-12-31): EPS=-1.16 | Chg30d=-0.088 | Revisions Net=+1 | Growth EPS=-0.7% | Growth Revenue=-19.1%